Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:GPCR News 8 December 2025 - 15 January 2026

Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

Pfizer shares rose 0.3% to $25.67 Thursday as investors weighed U.S. vaccine policy debates and the company’s growth outlook. The stock moved between $25.26 and $25.67 with 22.3 million shares traded. Pfizer will report Q4 results on Feb. 3, with guidance projecting 2026 revenue of $59.5–$62.5 billion and lower COVID-19 product sales. Competition in obesity drugs and AI-driven drug discovery remain in focus.
15 January 2026
····
Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics (GPCR) shares surged 7.5% to $83.76 Wednesday on over 1 million shares traded, fueled by buyout speculation and renewed interest in oral obesity drugs. Novo Nordisk executives signaled openness to acquisitions, while Structure reported Phase 2b data showing its oral GLP-1 drug aleniglipron led to 11.3% placebo-adjusted weight loss at 36 weeks. Viking Therapeutics and Terns Pharmaceuticals also rose sharply.
14 January 2026
······
Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

Structure Therapeutics shares surged about 14% midday Tuesday after a recent SEC filing revealed a $100 million upfront patent license deal with Roche’s Genentech for an oral GLP-1 drug. The stock rose to $79.24, up $9.88 from Monday’s close, as investors re-evaluated obesity-drug makers during the J.P. Morgan Healthcare Conference.
13 January 2026
····
Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics Inc. (NASDAQ: GPCR) is ending 2025 in the middle of one of biotech’s hottest battlegrounds: oral weight-loss medicines. As of Dec. 23, 2025, GPCR shares were trading around $67.50 in U.S. session data, after a volatile stretch driven by blockbuster obesity-trial headlines, a major equity financing, and a wave of analyst price-target updates. Below is a comprehensive roundup of the latest news, forecasts, and analysis available as of 23.12.2025, and what investors are watching next. What is Structure Therapeutics, and why does GPCR trade like a headline detector? Structure Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule
23 December 2025
····
Structure Therapeutics (GPCR) Stock: Why Shares Are Sliding on Dec. 16, 2025 After Breakout Obesity Pill Data and a $747.5M Offering

Structure Therapeutics (GPCR) Stock: Why Shares Are Sliding on Dec. 16, 2025 After Breakout Obesity Pill Data and a $747.5M Offering

Structure Therapeutics Inc. (NASDAQ: GPCR) is having a classic biotech moment on Tuesday, December 16, 2025: big catalyst, big financing, and now big volatility. Shares were down about 6% in Tuesday trading, recently around $60.73, after swinging between roughly $58.95 and $65.69 intraday. The pullback comes just days after the company reported positive topline Phase 2b results for its oral obesity candidate aleniglipron (GSBR-1290)—news that sparked a surge—followed immediately by an upsized equity raise that ultimately brought in about $747.5 million in gross proceeds. GlobeNewswire+1 Below is a detailed, up-to-date breakdown of the latest GPCR stock news (as of 16.12.2025),
16 December 2025
···
Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook

Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook

Structure Therapeutics Inc. (NASDAQ: GPCR) has suddenly become one of the most talked‑about obesity‑drug names on Wall Street. As of mid‑day on December 9, 2025, Structure Therapeutics stock was trading around $69.98, up roughly 100% in a single session after the company unveiled strong mid‑stage data for its once‑daily oral GLP‑1 obesity pill, aleniglipron. GlobeNewswire+2Investors+2 Over the past six months, GPCR has already delivered a multi‑bagger move, with one analyst note calculating a ~241% gain even before today’s opening bell. The stock now sits near its 52‑week high, with a 52‑week range of about $13.22 to $94.90 and a market
9 December 2025
··
Structure Therapeutics (NASDAQ: GPCR) Stock Explodes on Obesity Pill Data and $500M Offering: Latest News and Forecasts as of December 9, 2025

Structure Therapeutics (NASDAQ: GPCR) Stock Explodes on Obesity Pill Data and $500M Offering: Latest News and Forecasts as of December 9, 2025

Snapshot: Where Structure Therapeutics Stock Stands Today Structure Therapeutics Inc. (NASDAQ: GPCR) has suddenly moved from niche obesity biotech to front‑page market story. As of December 9, 2025, GPCR is trading around $69.98, up roughly 102% in a single session compared with its previous close near $34.56. The stock’s intraday range on December 8 ran from $44.74 to $94.90, marking a new 52‑week high, and lifting its market capitalization to about $4.25 billion.StockAnalysis+1 This explosive move followed positive Phase 2b trial data for the company’s oral GLP‑1 obesity drug aleniglipron and the announcement of a proposed $500 million public offering
9 December 2025
··
Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly and Company (NYSE: LLY) spent Monday, December 8, 2025, digesting a wave of news: a major reimbursement win for Mounjaro in China, a 15% dividend hike, new leukemia drug data, and the return of Nobel laureate Carolyn Bertozzi to its board. At the same time, intensifying competition and price cuts in the weight‑loss drug market kept pressure on the stock. By the closing bell, Lilly shares were trading just under the psychologically important $1,000 level, still near a trillion‑dollar valuation but roughly 10% below recent highs. StockAnalysis Key takeaways for LLY before the December 9, 2025 open How
9 December 2025
······
Structure Therapeutics (GPCR) Stock Soars on Obesity Pill Data: Latest News, Analyst Forecasts and 2026 Outlook (December 8, 2025)

Structure Therapeutics (GPCR) Stock Soars on Obesity Pill Data: Latest News, Analyst Forecasts and 2026 Outlook (December 8, 2025)

Structure Therapeutics Inc. (NASDAQ: GPCR) just turned a long‑anticipated clinical readout into a full‑blown stock market event. On Monday, December 8, 2025, the company released positive topline data from its ACCESS program for aleniglipron (GSBR‑1290), a once‑daily oral GLP‑1 receptor agonist for obesity. The market response was immediate: GPCR closed at $69.46, up about 101% on the day, after trading between $24.83 and an intraday high of $94.90. That move vaulted Structure into the front rank of the oral obesity drug race and forced investors, analysts and competitors to update their models in real time. Who is Structure Therapeutics and
8 December 2025
···
Biggest Stock Gainers Today: Biotech Breakouts and IBM–Confluent Deal Lead U.S. Market Movers (December 8, 2025)

Biggest Stock Gainers Today: Biotech Breakouts and IBM–Confluent Deal Lead U.S. Market Movers (December 8, 2025)

U.S. stocks traded mostly flat on Monday as Wall Street headed into a crucial Federal Reserve meeting, but under the surface the tape was anything but quiet. While the S&P 500 and Dow Jones Industrial Average hovered around unchanged and the Nasdaq 100 eked out a small gain, small‑cap and high‑beta names ripped higher, led by a wave of biotech catalysts and a blockbuster AI‑data takeover. According to StockAnalysis.com’s real‑time “Gainers Today” screen, Cemtrex, Structure Therapeutics, Wave Life Sciences, Fulcrum Therapeutics and iBio sat atop the leaderboard by early afternoon, each posting gains of nearly 50% or more. Many of
8 December 2025
········

Stock Market Today

Silver price rebound masks fresh stress after CME lifts margins again

Silver price rebound masks fresh stress after CME lifts margins again

7 February 2026
Spot silver surged 8.6% to $77.33 an ounce Friday after dropping below $65, but still lost over 8.7% for the week. CME Group raised margin requirements for COMEX silver futures to 18% from 15%, effective after Feb. 6. China’s UBS SDIC Silver Futures Fund hit its 10% down limit for a fifth session. Traders await key U.S. jobs and inflation data next week.
Gold price near $5,000: China keeps buying as CME margin hikes raise the stakes

Gold price near $5,000: China keeps buying as CME margin hikes raise the stakes

7 February 2026
China’s central bank raised gold reserves for a 15th month in January, reaching 74.19 million ounces worth $369.58 billion. Gold prices swung sharply, hitting a record near $5,600 before dropping to $4,403.24. CME Group hiked COMEX gold futures margins to 9% after recent volatility. U.S. jobs and inflation data are due next week after a delay.
Amazon stock (AMZN) slides on $200 billion AI capex plan — what Wall Street watches next week

Amazon stock (AMZN) slides on $200 billion AI capex plan — what Wall Street watches next week

7 February 2026
Amazon shares fell 5.6% to $210.32 on Friday after the company forecast 2026 capital spending would jump to $200 billion, up more than 50% from 2025. The drop came as the Dow closed above 50,000 for the first time. Amazon reported fourth-quarter net sales up 14% to $213.4 billion and operating income at $25 billion. Trading in Amazon was volatile, with 179 million shares changing hands.
Go toTop